In contrast, blocking TGF-β1 activation by GARP-expressing platelets was not required, as anti-tumor activity of combined GARP:TGF- β1/PD-1 blockade was conserved in MC38 tumor-bearing mice carrying a platelet-specific deletion of the Garp gene. This evidence concerns the gene LRRC32 and neoplasm.